Callisto Pharmaceuticals will merge with Synergy Pharmaceuticals following a definitive merger agreement between both the companies. As per the agreement, each outstanding share of Callisto common stock will be exchanged for 0.17 shares ...
Tags: Callisto Pharmaceuticals, Synergy Pharmaceuticals, Callisto common stock
Synergy Pharmaceuticals has signed an asset purchase agreement to acquire FV-100 shingles drug from Bristol-Myers Squibb Company. FV-100 is an orally available nucleoside analogue, at present being developed for the treatment of shingles, ...
Tags: Synergy Pharmaceuticals, treatment of shingles, FV-100